Announcements Trials
Browse Landscape

Phase

Phase 3 54Phase 2 43Phase 1 23Phase 1/2 14Phase 4 10Phase 2/3 2Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

OTHER 12OTHER_GOV 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9anlotinib 7Trastuzumab 7Injections 7Rituximab 6atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5venetoclax 4Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Albumin-Bound Paclitaxel 4sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × Letrozole × Clear all
NCT00535418 2017-09-05

Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

Novartis

Phase 2/3 Completed
35 enrolled
Breast

Breast Neoplasms

NCT00333047 2009-11-19

Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy

Novartis

Phase 2/3 Completed
24 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡